Assessment of Safety and Efficacy of Romiplostim in Live Donor Liver Transplant Recipients- A Prospective Randomized Open Label Trial - not applicable

开始日期2024-05-10

申办/合作机构-

100 项与罗米司亭相关的临床结果

登录后查看更多信息

100 项与罗米司亭相关的转化医学

登录后查看更多信息

100 项与罗米司亭相关的专利（医药）

登录后查看更多信息

688

项与罗米司亭相关的文献（医药）

2024-06-01·Recent patents on biotechnology

A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli

Review

作者: Hashemzehi, Ahmad ; Moradbeygi, Fatemeh ; Jamshidi, Mehrnaz ; Hashemzaei, Masoud ; Ghoshoon, Mohammad Bagher

Abstract::

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder determined by immune-mediated platelet demolition and reduction of platelet production. Romiplostim is a new thrombopoiesis motivating peptibody that binds and stimulates the human thrombopoietin receptor the patent of which was registered in 2008. It is used to treat thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Romiplostim is a 60 kDa peptibody designed to inhibit cross-reacting immune responses. It consists of four high-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc domain. Escherichia coli is a good host for the fabrication of recombinant proteins such as romiplostim. The expression of a gene intended in E. coli is dependent on many factors such as a protein’s inherent ability to fold, mRNA’s secondary structure, its solubility, its toxicity preferential codon use, and its need for post-translational modification (PTM). This review focuses on the structure, function, mechanism of action, and expressive approach to romiplostim in E. coli.

2024-01-01·Blood reviews

Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists

Review

作者: Al-Samkari, Hanny

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of antineoplastic therapy, resulting in antineoplastic therapy dose reductions, treatment delays, treatment discontinuation, and morbid bleeding events. Despite several decades of research into thrombopoietic growth factors in CIT, there are presently no available U.S. FDA- or EMA-approved agents to treat CIT. However, a respectable body of evidence has been published evaluating the thrombopoietin receptor agonists (TPO-RAs) for the management and prevention of CIT in patients with solid tumors, and critical studies are ongoing with the TPO-RAs romiplostim and avatrombopag. When employed in the appropriate patient population and used properly, TPO-RAs can successfully and safely manage CIT for extended periods of time with minimal apparent risks. This comprehensive review discusses the evidence for TPO-RAs in CIT in patients with solid tumors, provides detailed guidance for their use in the clinic, and discusses ongoing essential clinical trials in management of CIT.

2023-12-31·Hematology (Amsterdam, Netherlands)

Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)

Article

作者: Eriksson, Daniel ; Prince, Samantha ; Jansen, A J Gerard ; McDonald, Vickie ; Wilson, Koo ; Zwaginga, Jaap Jan ; Daykin-Pont, Owen ; Geldman, Emma ; Morgan, Mervyn ; Newland, Adrian ; Bastiaanse, Mieke

OBJECTIVE:

Identify patient experience and preference towards thrombopoietin-receptor agonists (TPO-RAs) in treatment of immune thrombocytopenia (ITP) in the Netherlands.

METHODS:

The Thrombopoietin-Receptor Agonist Patient experience (TRAPeze) survey used a discrete choice experiment (DCE) to elicit patient preferences and a patient burden survey (PBS) to evaluate the clinical and social impact of ITP. TRAPeze collected responses from 6th October to 19th November 2021.

RESULTS:

Seventy-six respondents completed the DCE: treatment preference appeared to be driven by method of administration (odds ratio [OR] 4.33; 95% confidence interval [CI] 2.88-6.52), frequency of dosing (OR 2.33; 95% CI 1.86-2.92) and drug-food interactions (OR 1.91; 95% CI 1.54-2.37). Respondents preferred therapies delivered orally over subcutaneous injection (OR 4.22; 95% CI 2.76-6.46), dosed once weekly over once daily (OR 2.37; 95% CI 1.58-3.54) and without food restrictions over with restrictions (OR 1.90; 95% CI 1.52-2.38). Sixty-nine respondents completed the DCE and PBS (mean [range] age 53 [19-83] years, 65% female). Seven incomplete PBS responses were excluded from analysis. Respondents were currently, or most recently, receiving eltrombopag (n = 43) or romiplostim (n = 26), of which 30% (n = 21/69) had previously received another TPO-RA. Loss (29%, n = 6/21) and lack (29%, n = 6/21) of response were the most common reasons for switching TPO-RA. Only 28% (n = 18/65) of respondents felt their TPO-RA increased energy levels.

CONCLUSION:

Patients preferred therapies delivered orally, dosed less frequently and without food restrictions. QoL of ITP patients on TPO-RAs can be improved; the burden analyses presented can inform future efforts towards this.

项与罗米司亭相关的新闻（医药）

2024-06-24

·FierceBiotech

Takeda’s anti-CD38 antibody on track for phase 3 after boosting platelet count in bleeding disorder

Around 20% of patients with ITP don’t achieve a platelet count above 50,000/uL despite receiving the available first- and second-line treatment. Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggest that the anti-CD38 antibody could still “transform treatment” of primary immune thrombocytopenia (ITP). Last month, the Japanese pharma deprioritized the development of mezagitamab, also known as TAK-079, in myasthenia gravis and systemic lupus erythematosus as part of a wider pipeline shakeup. But the team said at the time that they were still planning to continue to clinically evaluate the antibody in ITP. At the International Society on Thrombosis and Haemostasis Congress on June 22, Takeda unveiled late-breaking data from a 41-patient phase 2b trial assessing three doses of mezagitamab for the immune-mediated bleeding disorder. The trial’s primary endpoint was the percentage of patients with at least one grade 3 or higher treatment-emergent adverse event (TEAE), serious adverse event (SAE) and adverse events (AEs) leading to discontinuation of treatment. The company reported that the antibody had a favorable safety profile with no new safety signals discovered. The rate of TEAEs leading to discontinuation was 14.3% across the three dose cohorts compared to 0% for the placebo group, Takeda said. The number of TEAEs at grade 3 or above was lower, at 17.9%, in the mezagitamab cohorts compared to 23.1% in the placebo cohort while 14.3% of the mezagitamab patients experienced a SAE compared to 7.7% on placebo. ITP involves the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. All three doses of mezagitamab were shown to improve platelet response compared to placebo, with “rapid and sustained increases in platelet counts” above the 50,000/μL therapeutic threshold that persisted for eight weeks after the eight-week course of weekly doses. This illustrated “the rapid and post-therapy effects of mezagitamab on platelet response,” Takeda said. When assessing various measures of platelet response, the company noted that these were all highest in patients who received the highest, 600 mg, dose of mezagitamab. Takeda highlighted an 81.8% complete platelet response, a 90.9% clinically meaningful platelet response and a 100% hemostatic platelet response among these patients. Novartis’ Promacta, Amgen’s Nplate and Sobi’s Doptelet are all approved for ITP. Argenx had been aiming Vyvgart at the condition but the FcRn drug flunked primary and secondary endpoints in a phase 3 study in November 2023. Around 20% of patients with ITP don’t achieve a platelet count above 50,000/uL despite receiving the available first- and second-line treatments, Takeda explained in the release. This means that maintaining a platelet count of 50,000/uL or more for a sustained period has become the precedent for getting a new drug approved in the indication. “Despite treatment with currently available therapies, there is still a significant disease burden and need for a disease-modifying treatment that people living with ITP can tolerate,” David Kuter, M.D., who presented the findings at the congress, said in an accompanying press release.

临床结果临床3期临床2期上市批准

2024-06-19

·米内网

【重磅】齐鲁拿下$33亿明星药首仿

精彩内容近日，国家药监局官网显示，齐鲁制药申报的4类仿制药氯苯唑酸葡胺软胶囊获批生产，为国内首仿+首家过评。氯苯唑酸是辉瑞研发的一款罕见病用药，2023年全球销售额约达33亿美元。氯苯唑酸是由辉瑞研发的一种口服转甲状腺素蛋白稳定剂，可以阻止转甲状腺素蛋白分解，进而防止淀粉样蛋白原纤维的形成并延缓神经疾病的进展，适用于转甲状腺素蛋白淀粉样变多发性神经病(ATTR-PN)的治疗。据悉，ATTR-PN是一种遗传性罕见致死性神经退行性疾病，可累及多系统受损。目前氯苯唑酸已在英国、德国、法国等超过45个国家和地区获批治疗ATTR-PN，商品名为Vyndaqel（氯苯唑酸葡胺软胶囊）和Vyndamax（氯苯唑酸软胶囊）。米内网数据显示，2021年辉瑞的氯苯唑酸系列产品全球销售额突破20亿美元，2023年涨至约33亿美元。近年来辉瑞的氯苯唑酸系列产品全球销售情况（单位：百万美元）来源：米内网跨国上市公司数据库目前辉瑞的氯苯唑酸葡胺软胶囊、氯苯唑酸软胶囊均已获批进入国内市场。仿制药申报方面，齐鲁制药、南京正大天晴制药的氯苯唑酸葡胺软胶囊于2023年1月、2月先后报产，其中齐鲁制药的产品已于近日获批生产，顺利拿下首仿。氯苯唑酸系列产品国内申报进度来源：米内网中国申报进度（MED）数据库米内网数据显示，2024年以来，齐鲁制药有13个仿制药获批生产并视同过评（含非首次获批），其中氯苯唑酸葡胺软胶囊、盐酸苯达莫司汀注射用浓溶液为国内首仿（含剂型首仿），泊马度胺胶囊国产第2家获批，艾曲泊帕乙醇胺片国产第3家获批。 2024年以来齐鲁制药获批上市的品种来源：米内网中国申报进度（MED）数据库新药方面，今年以来，齐鲁制药研发的1类新药伊鲁阿克片新适应症获批上市，覆盖全线ALK阳性晚期非小细胞肺癌患者；生物药3.4类新药注射用罗普司亭国产首家获批，用于治疗免疫性血小板减少症(ITP)；3.3类生物类似药地舒单抗注射液新适应获批，用于治疗不可手术切除或者手术切除可能导致严重功的障碍的骨巨细胞瘤(GCTB)。资料来源：米内网数据库、国家药监局官网等本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准生物类似药

2024-06-11

·PRNewswire

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

放射疗法

100 项与罗米司亭相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08990	罗米司亭	B02BX04	DB05332

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性放射综合征	美国	Amgen, Inc.	2021-01-28
再生障碍性贫血	日本	Kyowa Kirin Co., Ltd.	2019-06-18
慢性特发性血小板减少性紫癜	日本	Kyowa Kirin Co., Ltd.	2011-01-21
免疫性血小板减少症	美国	Amgen, Inc.	2008-08-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床3期	-	Amgen, Inc.	2018-01-27
血小板减少症	临床3期	-	Amgen, Inc.	2018-01-27
难治性重度再生障碍性贫血	临床2期	-	Amgen, Inc.	2023-08-31
胶质母细胞瘤	临床2期	西班牙	Amgen, Inc.	2022-09-13
胶质母细胞瘤	临床2期	瑞士	Amgen, Inc.	2022-09-13
多发性骨髓瘤	临床2期	美国	Amgen, Inc.	2020-07-14
晚期非小细胞肺癌	临床2期	美国	Amgen, Inc.	2006-12-01
晚期非小细胞肺癌	临床2期	奥地利	Amgen, Inc.	2006-12-01
晚期非小细胞肺癌	临床2期	加拿大	Amgen, Inc.	2006-12-01
晚期非小细胞肺癌	临床2期	德国	Amgen, Inc.	2006-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2024	N/A	实体瘤	-	Romiplostim	廠膚繭壓積糧顧壓蓋淵(窪衊簾壓鹽範襯艱艱衊) = 淵鹹艱獵鬱顧構鏇鬱膚醖鑰選廠網衊製顧鬱餘 (製鑰艱蓋膚醖襯鏇夢齋, 72.47 ~ 87.48)	积极	2024-05-24
CARMEN-France (EHA2024)	N/A	-	1,751	Romiplostim	繭範糧製醖築鬱齋廠積(鹹窪築顧願築艱構繭淵) = 構鏇積鏇製廠壓顧壓選衊顧糧鏇繭齋醖範顧衊 (鏇構窪簾鹹觸壓簾膚壓 ) 更多	积极	2024-05-14
EHA2024	N/A	再生障碍性贫血一线 PNH clone	19	Romiplostim, Cyclosporine, Danazol	衊鹽鬱鑰餘範選範膚夢(製蓋鬱築膚築膚夢膚衊) = 製願鏇艱遞築鏇鏇築遞窪夢窪獵窪夢鹹觸廠鏇 (獵鏇艱壓選獵蓋衊廠鏇 )	积极	2024-05-14
EHA2024	N/A	再生障碍性贫血一线 PNH clone	19	Romiplostim, Cyclosporine, Danazol, Anti-thymocyte Globulin	衊鹽鬱鑰餘範選範膚夢(製蓋鬱築膚築膚夢膚衊) = 製構選蓋壓顧積獵窪鑰窪夢窪獵窪夢鹹觸廠鏇 (獵鏇艱壓選獵蓋衊廠鏇 )	积极	2024-05-14
NCT04478123 (CTgov)	临床2期	霍奇金淋巴瘤 \| 血小板减少症 \| 多发性骨髓瘤	62	Romiplostim	獵艱鹽衊網繭簾鑰繭齋(繭糧簾夢獵繭襯憲範膚) = 積襯鬱壓獵繭艱夢窪鑰衊襯窪顧簾顧膚廠網襯 (範餘鹹醖夢襯觸壓構顧, 廠遞顧願積夢膚獵襯夢 ~ 鑰壓鏇鏇淵築構選願選) 更多	-	2024-02-14
ASH2023	N/A	血小板减少症	130	Romiplostim	襯壓壓鹹鏇憲糧獵鏇衊(鑰壓壓憲獵糧憲選鏇窪) = 齋製夢鹽壓範遞糧繭網淵範壓鬱鑰鬱願廠鹹膚 (糧鏇築顧糧襯顧鹹範築 )	-	2023-12-11
ASH2023	N/A	血小板减少症	130	Granulocyte-colony stimulating factor (GCSF)	襯壓壓鹹鏇憲糧獵鏇衊(鑰壓壓憲獵糧憲選鏇窪) = 築廠築簾艱顧壓醖製窪淵範壓鬱鑰鬱願廠鹹膚 (糧鏇築顧糧襯顧鹹範築 )	-	2023-12-11
ASH2023	N/A	免疫性血小板减少症二线	87	Romiplostim	鬱鏇鹽壓顧鹽淵願餘鹽(觸積餘願願鏇網衊遞繭) = 願衊積願壓廠膚鹹鬱構壓鹽簾憲簾鬱鹹齋衊壓 (糧積獵壓憲艱簾繭製範 ) 更多	-	2023-12-11
ASH2023	N/A	免疫性血小板减少症二线	87	Eltrombopag	鬱鏇鹽壓顧鹽淵願餘鹽(觸積餘願願鏇網衊遞繭) = 鏇壓觸夢齋壓製齋鏇鹽壓鹽簾憲簾鬱鹹齋衊壓 (糧積獵壓憲艱簾繭製範 ) 更多	-	2023-12-11
NCT04671901 (CTgov)	临床2期	血小板增多症 \| 血小板减少症 \| 儿童恶性实体瘤	2	Romiplostim	夢鑰襯鬱鏇壓鹽選鹽衊(餘鹹鹹艱遞醖築壓窪鹽) = 憲獵夢醖鑰鬱醖顧觸艱鹽鏇鬱鬱齋衊蓋鹽窪憲 (淵衊構淵蓋遞鏇餘淵衊, 憲糧糧膚選網築餘糧衊 ~ 壓鏇糧夢鹽簾鑰獵繭淵) 更多	-	2023-11-18
CTR20150395 \| NCT02868099 (Pubmed)	临床3期	免疫性血小板减少症二线	202	Romiplostim	蓋繭遞糧鏇積齋簾鹽範(簾觸願製鹹觸壓願糧繭) = 1.3% vs 11.8% 觸選蓋獵鬱鑰衊鹹餘艱 (鑰夢願繭襯顧遞簾製觸 )	积极	2023-07-01
NCT04095936 (EHA2023)	临床2/3期	再生障碍性贫血一线	24	Romiplostim combined with Cyclosporine A	觸夢壓窪範齋蓋憲積夢(選遞顧鑰鹽顧鹽鏇繭製) = 餘膚鹹蓋鏇襯鏇築網餘顧顧鏇蓋獵遞鬱壓餘築 (築獵鑰憲衊廠築膚製積 ) 更多	-	2023-06-08
EHA2023	N/A	免疫性血小板减少症	-	Romiplostim (Group 1)	構憲鏇網網鹽膚壓製艱(繭積觸繭繭醖鹽鹽簾遞) = 製襯構憲衊選鑰糧艱觸廠廠範壓糧築製憲鑰範 (願構夢齋獵築顧襯選夢 ) 更多	-	2023-06-08
EHA2023	N/A	免疫性血小板减少症	-	Romiplostim (Group 2)	構憲鏇網網鹽膚壓製艱(繭積觸繭繭醖鹽鹽簾遞) = 夢構製窪膚鬱壓衊鹹遞廠廠範壓糧築製憲鑰範 (願構夢齋獵築顧襯選夢 ) 更多	-	2023-06-08